Toxicology News and Research

Latest Toxicology News and Research

Albemarle, Pharmacore partner to provide manufacturing capabilities for high volume capacity projects

Albemarle Corporation, a leading global provider of custom manufacturing services, announced today it will partner with PharmaCore to provide manufacturing capabilities for customers with projects that require high volume capacity.

16 Feb 2010

Cal-EPA intents to add BPA to state's list of chemicals known to cause cancer

The California Environmental Protection Agency signaled intent to add bisphenol A (BPA) to the state's list of chemicals known to cause cancer or birth defects, adding to evidence the chemical should be banned from food and beverage containers.

12 Feb 2010

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.

11 Feb 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today its execution of a purchase agreement to acquire the Discovery and Preclinical business of MDS Pharma Services with facilities in Bothell, Washington; Lyon, France; and Taipei, Taiwan. Company headquarters will remain in Concord, Ohio.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

11 Feb 2010

Alcohol and energy drinks may create a dangerous mix

Energy drinks, favored among young people for the beverages' caffeine jolt, also play a lead role in several popular alcoholic drinks, such as Red Bull and vodka. But combining alcohol and energy drinks may create a dangerous mix, according to University of Florida research.

10 Feb 2010

Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

Silence Therapeutics plc today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology. Known as PKN-3, the target is a protein kinase C-related molecule that is believed to play an important role in the growth of cancer cells, as well as metastasis formation.

8 Feb 2010

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

4 Feb 2010

Wolters Kluwer Health relaunches flagship drug information reference as Facts & Comparisons eAnswers

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has relaunched its flagship drug information reference as Facts & Comparisons® eAnswers.

4 Feb 2010

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an agreement to leverage the computational chemistry expertise of Dr. John Trent, Associate Professor, Department of Medicine at the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center), to accelerate the identification of new clinical candidates for the prevention and treatment of cancer.

4 Feb 2010

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Entelos, Inc., a simulation and modeling company focused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled “Apparatus and Methods for Assessing Metabolic Substrate Utilization” to the Company. These methods further strengthen the Entelos® Metabolism PhysioLab® platform and leverage insights about human physiology that can lead to improved diagnosis, clinical testing, and personalized treatment across a highly variable patient population.

2 Feb 2010

Scientists and engineers conduct research on environmental health impacts of nanomaterials

As researchers around the world hasten to employ nanotechnology to improve production methods for applications that range from manufacturing materials to creating new pharmaceutical drugs, a separate but equally compelling challenge exists.

2 Feb 2010

Millennium Laboratories supports CLIA certification for Florida clinical laboratories

Millennium Laboratories, Inc., a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, today announced the company’s support for a recent decision by the Florida Pain Management Clinic Standards of Practice Joint Committee to amend draft regulatory language related to the certification of clinical laboratories providing services to pain physicians operating in the state.

2 Feb 2010

Hormones & Cancer: A new journal from The Endocrine Society

Today, The Endocrine Society unveiled its newest journal, Hormones & Cancer. This bi-monthly journal will include research articles covering all aspects of hormone action on cancer causation, progression, dependence, prevention, resistance and treatment.

29 Jan 2010

St. Joseph's Regional Medical Center opens Geriatric ED to treat senior patients

St. Joseph's Regional Medical Center, Paterson, NJ, recently opened the region's first dedicated Geriatric Emergency Department (Geriatric ED). Treating patients age 65 and older, the department is designed to meet the complex needs of older patients in a senior-friendly environment.

27 Jan 2010

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

27 Jan 2010

Microbia's beta-carotene receives 'GRAS' status for food and beverage applications

Microbia, Inc., today announced that a panel of independent experts has determined its bio-based β-carotene (beta-carotene) to be GRAS (Generally Recognized As Safe) for both food and beverage applications.

27 Jan 2010

Progress in Anadys Pharmaceuticals' Phase II study of ANA598 announced

Anadys Pharmaceuticals, Inc. today announced that ANA598 dosing has been completed in the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.

22 Jan 2010

FDA accepts ACT Biotech's ACTB1003 IND

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.

22 Jan 2010

Toxicology News and Research

Latest Toxicology News and Research

Albemarle, Pharmacore partner to provide manufacturing capabilities for high volume capacity projects

Cal-EPA intents to add BPA to state's list of chemicals known to cause cancer

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Alcohol and energy drinks may create a dangerous mix

Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

Wolters Kluwer Health relaunches flagship drug information reference as Facts & Comparisons eAnswers

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Scientists and engineers conduct research on environmental health impacts of nanomaterials

Millennium Laboratories supports CLIA certification for Florida clinical laboratories

Hormones & Cancer: A new journal from The Endocrine Society

St. Joseph's Regional Medical Center opens Geriatric ED to treat senior patients

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

Microbia's beta-carotene receives 'GRAS' status for food and beverage applications

Progress in Anadys Pharmaceuticals' Phase II study of ANA598 announced

FDA accepts ACT Biotech's ACTB1003 IND

Forensics And Toxicology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Toxicology News and Research

Latest Toxicology News and Research

Forensics And Toxicology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in